Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity

Bibliography

• D'Incalci M, Sessa C. DNA minor groove binding ligands: a new class of anticancer agents. Expert Opin Investig Drugs 1997;6:875-84
   PubMedGoogle Scholar
• Marchini S, Cozzi P, Beria I, Sequence-specific DNA alkylation of novel tallimustine derivatives. Anticancer Drug Des 1998;13:193-205
   PubMedGoogle Scholar
• Sessa C, Pagani O, Zurlo MG, Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann Oncol 1994;5:901-7
   PubMed Web of Science ®Google Scholar
• Broggini M, Marchini S, Fontana E, Brostallicin: a new concept in minor groove DNA binder development. Anticancer Drugs 2004;15:1-6
   PubMed Web of Science ®Google Scholar
• D'Alessio R, Geroni C, Biasoli G, Structure activity relationship of novel distamycin A derivatives: synthesis and antitumor activity. Bioorg Med Chem Lett 1994;4:1467-72
   Web of Science ®Google Scholar
• Marchini S, Ciro M, Gallinari F, Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity. Br J Cancer 1999;80:991-97
   PubMed Web of Science ®Google Scholar
• Beria I, Caldarelli M, Geroni C, Cytotoxic alpha-bromoacrylic derivatives of low molecular weight. Bioorg Med Chem Lett 2002;12:1467-71
   PubMed Web of Science ®Google Scholar
• Nagle CM, Chenevix-Trench G, Spurdle AB, Webb PM. The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer 2007;43:283-90
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Scambia G, Damia G, Glutathione S-transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome. Ann Oncol 1997;8:343-50
   PubMed Web of Science ®Google Scholar
• Tagliabue G, Pifferi A, Balconi G, Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to DNA-interacting anti-neoplastic agents. Int J Cancer 1993;54:435-42
   PubMed Web of Science ®Google Scholar
• Hill BT. Collateral sensitivity and cross-resistance. Antitumor Drug Resist 1984;673-4
   Google Scholar
• Cozzi P. A new class of cytotoxic DNA minor groove binders: alpha-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers. Farmaco 2001;56:57-65
   PubMedGoogle Scholar
• Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983;52:711-60
   PubMed Web of Science ®Google Scholar
• Fedier A, Fowst C, Tursi J, Brostallicin (PNU-166196) – a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells. Br J Cancer 2003;89:1559-65
   PubMed Web of Science ®Google Scholar
• Geroni C, Marchini S, Cozzi P, Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res 2002;62:2332-6
   PubMed Web of Science ®Google Scholar
• Beria I, Baraldi PG, Cozzi P, Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners. J Med Chem 2004;47:2611-23
   Google Scholar
• Nakayama M, Gonzalgo ML, Yegnasubramanian S, GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004;91:540-52
   PubMedGoogle Scholar
• Broggini M, Sabatino MA, Geroni C, Weitman S. Antitumor activity of brostallicin on human prostatic cancer: role of combinatipon with hypomethylating agents. AACR-NCI-EORTC Conference on Molecular Targets, 2007; abstract A288
   Google Scholar
• Wolkenberg SE, Boger DL. Mechanisms of in situ activation for DNA-targeting antitumor agents. Chem Rev 2002;102:2477-95
   PubMed Web of Science ®Google Scholar
• Ciomei M, Pastori W, Cozzi P, Geroni MC. Induction of apoptosis with a new distamycin derivative. Proc Am Assoc Cancer Res 1999;40:1490
   Google Scholar
• Guirouilh-Barbat J, Zhang YW, Pommier Y. Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin. Mol Cancer Ther 2009;8:1985-94
   PubMed Web of Science ®Google Scholar
• Sabatino MA, Colombo T, Geroni C, Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin. Clin Cancer Res 2003;9:5402-8
   PubMed Web of Science ®Google Scholar
• Nishiyama M, Yamamoto W, Park JS, Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999;5:2620-8
   PubMed Web of Science ®Google Scholar
• Geroni C, Pesenti E, Ballinari D, Combination treatment of new molecular- targeted therapies and the DNA minor groove binder brostallicin. Eur J Cancer Suppl 2004;4:95
   Google Scholar
• Fontana E, Pignatti A. Synthesis of brostallicin (PNU-166196A) labelled with H and C. J Label Comp Radiopharm 2002;45:899-909
   Web of Science ®Google Scholar
• Ghielmini M, Bosshard G, Capolongo L, Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer 1997;75:878-83
   PubMed Web of Science ®Google Scholar
• Ten Tije AJ, Verweij J, Sparreboom A, Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer. Clin Cancer Res 2003;9:2957-64
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Howard M, Hande KR, A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin Cancer Res 2004;10:468-75
   PubMed Web of Science ®Google Scholar
• Lorusso D, Fornari G, Caponigro F, Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors. ECCO 14 The European Cancer Conference 2007. Available from: http://www.CTICSeattle.com [last accessed July 2009]
   Google Scholar
• Lorusso D, Zanaboni F, Scalone S, Phase II exploratory study of brostallicin in patients with ovarian cancer resistant/refractory to platinum-based chemotherapy. J Clin Oncol 2008;26
   Web of Science ®Google Scholar
• Leahy M, Ray-Coquard I, Verweij J, Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2007;43:308-15
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-9
   PubMed Web of Science ®Google Scholar
• Goto S, Ihara Y, Urata Y, Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi. FASEB J 2001;15:2702-14
   PubMed Web of Science ®Google Scholar
• Ferruzzi E, Franceschini R, Cazzolato G, Blood glutathione as a surrogate marker of cancer tissue glutathione S-transferase activity in non-small cell lung cancer and squamous cell carcinoma of the head and neck. Eur J Cancer 2003;39:1019-29
   PubMed Web of Science ®Google Scholar
• Jeronimo C, Usadel H, Henrique R, Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002;60:1131-5
   PubMed Web of Science ®Google Scholar